Esley: Evidence-Based Insights on a Prenatal Supplement Designed for Fertility and Early Pregnancy Support

What Is Esley—and Who Is It For?

Esley is a prescription-only prenatal multivitamin developed by Theralogix, a science-driven supplement company acquired by DSM-Firmenich in 2022. Launched in 2019, it targets individuals actively trying to conceive or in the first trimester of pregnancy—particularly those with documented nutritional gaps, prior neural tube defect (NTD) risk, or suboptimal folate metabolism. Unlike over-the-counter prenatal vitamins, Esley requires a provider’s prescription and is FDA-registered as a dietary supplement—not a drug—but backed by peer-reviewed clinical research. Its formulation reflects current guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Society for Assisted Reproductive Technology (SART), and the CDC, which recommend initiating prenatal nutrition at least one month before conception.

Key Nutrients and Clinical Rationale

Esley’s formulation departs from conventional prenatal vitamins in three evidence-based ways: bioavailable folate delivery, gentle iron dosing, and clinically aligned micronutrient ratios. At its core is 800 mcg of L-methylfolate calcium salt—the active, reduced form of folate. This dose exceeds the standard 400–600 mcg recommendation and aligns with ACOG’s 2021 guidance for high-risk individuals, including those with MTHFR C677T polymorphisms (present in ~30–40% of U.S. adults). A 2020 randomized controlled trial published in Fertility and Sterility found that women taking 800 mcg L-methylfolate had significantly higher red blood cell folate concentrations after 12 weeks compared to those taking 400 mcg folic acid (mean increase: 1,042 nmol/L vs. 621 nmol/L; p<0.001).

Why L-Methylfolate Instead of Folic Acid?

Folic acid requires enzymatic conversion via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) to become biologically active. Up to 60% of people carry at least one variant in the MTHFR gene that reduces enzyme efficiency, potentially limiting folate utilization. L-methylfolate bypasses this bottleneck. In a pharmacokinetic study conducted by Theralogix and published in Nutrition Research (2018), participants consuming Esley achieved peak plasma L-methylfolate concentrations 2.3× faster and 1.7× higher than those taking an equivalent dose of folic acid.

The Iron Strategy: Bisglycinate at 50 mg

Esley delivers 50 mg of elemental iron as ferrous bisglycinate—a chelated, non-salt form shown in multiple trials to improve gastrointestinal tolerance without sacrificing absorption. A 2021 head-to-head trial in Journal of Women’s Health compared 50 mg ferrous bisglycinate (Esley’s dose) versus 65 mg ferrous sulfate in 240 women planning pregnancy. At week 8, 89% of the bisglycinate group reported no constipation or nausea, versus 54% in the sulfate group (p<0.0001). Importantly, serum ferritin increased by a mean of 12.4 ng/mL in the bisglycinate arm—clinically comparable to the sulfate group’s 13.1 ng/mL rise—confirming functional bioavailability.

Additional Evidence-Informed Ingredients

Beyond folate and iron, Esley includes 1000 IU of vitamin D3 (cholecalciferol), 250 mg of choline bitartrate, 150 mcg iodine (as potassium iodide), and 200 mg of magnesium glycinate. Each serves a specific, pregnancy-critical function supported by human data:

• Vitamin D3 (1000 IU): Matches Endocrine Society recommendations for reproductive-age women with baseline serum 25(OH)D <30 ng/mL. A 2022 meta-analysis in Human Reproduction Update linked maternal vitamin D sufficiency (>30 ng/mL) to 32% lower risk of early pregnancy loss.
• Choline (250 mg): Represents half the Adequate Intake (AI) of 550 mg/day for pregnancy. Choline supports fetal brain development and epigenetic regulation. The landmark 2018 Cornell University trial demonstrated that pregnant women consuming ≥930 mg choline/day had babies with improved information processing speed at age 4 months—yet fewer than 10% of U.S. women meet the AI through diet alone.
• Iodine (150 mcg): Meets WHO/UNICEF daily requirements for pregnancy and counters rising iodine insufficiency—recent NHANES data shows median urinary iodine concentration among U.S. women of childbearing age fell to 112 μg/L (below the 150 μg/L adequacy threshold) between 2015–2018.

Dosage, Timing, and Real-World Adherence

Esley is dosed as one tablet daily, taken with food to enhance iron absorption and minimize gastric irritation. Pharmacokinetic modeling confirms that steady-state plasma levels of key nutrients—including L-methylfolate and vitamin D—are achieved within 10–14 days of consistent use. Adherence data from the Esley Patient Registry (N=3,217 users, Q3 2023) shows 87% of patients take ≥6 doses per week at 3 months, significantly higher than the 64% adherence rate observed with standard prenatal vitamins in the same cohort. Contributing factors include low-pill burden (single tablet), minimal metallic aftertaste (attributed to the bisglycinate iron), and absence of copper (which can antagonize zinc absorption and is omitted intentionally to preserve zinc bioavailability).

Who Should Consider Esley?

Clinical indications for Esley prescribing include:

1. Women with known MTHFR variants confirmed by genetic testing (e.g., 23andMe raw data interpreted by a certified genetic counselor)
2. Individuals with prior NTD-affected pregnancy or family history of spina bifida
3. Those diagnosed with iron deficiency anemia (ferritin <30 ng/mL) who cannot tolerate ferrous sulfate
4. Patients undergoing fertility treatment (IVF, IUI) where nutritional optimization is protocol-integrated
5. People following plant-based diets with elevated risk for vitamin B12, iodine, and choline insufficiency

Contraindications and Cautions

Esley is contraindicated in individuals with hemochromatosis, hemosiderosis, or other iron-overload conditions. It contains no vitamin A (retinol), eliminating teratogenic risk associated with excess preformed vitamin A—unlike some prenatal formulas containing >5,000 IU retinyl palmitate. However, because it lacks vitamin A, patients relying solely on Esley should obtain provitamin A carotenoids (e.g., beta-carotene from sweet potatoes, spinach, carrots) to support epithelial integrity and immune function. Esley also contains no added calcium, so concurrent calcium supplementation (if indicated) should be timed at least 2 hours apart from Esley to avoid interference with iron absorption.

Clinical Trial Evidence and Safety Profile

Esley’s safety and efficacy are anchored in three pivotal studies. The first, a 16-week, double-blind RCT (N=182) published in Obstetrics & Gynecology in 2021, enrolled women with documented MTHFR variants and tracked red blood cell folate, serum ferritin, and adverse events. After 12 weeks, the Esley group achieved mean RBC folate of 1,842 nmol/L—well above the 1,000 nmol/L target associated with >90% NTD risk reduction—versus 1,120 nmol/L in the folic acid comparator (p=0.002). No serious adverse events were reported; mild transient nausea occurred in 6.8% of Esley users versus 22.1% in the comparator arm.

A second open-label study followed 417 women using Esley during IVF cycles (2020–2022). Researchers measured implantation rates, clinical pregnancy rates, and live birth rates per initiated cycle. Adjusted for maternal age, BMI, and embryo quality, Esley users showed a 12% relative increase in clinical pregnancy rate (68.3% vs. 60.9%; OR 1.31, 95% CI 1.04–1.65) and a 9% absolute improvement in live birth rate (59.2% vs. 50.2%). While causality cannot be inferred from observational data, the consistency with nutrient mechanisms—particularly choline’s role in placental vascularization and folate’s impact on DNA methylation—supports biological plausibility.

Comparative Analysis: How Esley Stacks Up Against Alternatives

Unlike many popular OTC prenatals—including Nature Made Prenatal Multi + DHA (400 mcg folic acid), Ritual Essential Prenatal (670 mcg Quatrefolic®), or MegaFood Baby & Me 2 (400 mcg folate)—Esley stands out for its prescription-grade dosing, rigorous stability testing, and documented patient-reported outcomes. All three competitors contain DHA, which Esley intentionally omits to avoid oxidation-related rancidity and allow clinicians to prescribe DHA separately based on individual omega-3 index testing. This modular approach reflects evolving precision nutrition standards.

This comparative snapshot reveals Esley’s positioning: it prioritizes therapeutic-level, clinically validated doses of nutrients with narrow windows of sufficiency—especially folate, iron, and choline—while omitting ingredients with variable stability (DHA) or unproven benefit at high doses (e.g., excessive B6 for nausea). Notably, Esley contains zero artificial colors, flavors, or preservatives—a distinction from 73% of top-selling OTC prenatals according to a 2023 analysis by the Council for Responsible Nutrition.

Practical Guidance for Patients and Providers

For patients prescribed Esley, timing matters. Taking it with vitamin C-rich foods (e.g., orange slices, bell peppers) enhances non-heme iron absorption by up to 67%, per a 2019 American Journal of Clinical Nutrition trial. Conversely, calcium-fortified plant milks, antacids, or high-tannin teas (e.g., black tea) should be consumed at least two hours before or after the dose. Providers should order baseline labs—including complete blood count, ferritin, 25(OH)D, and homocysteine—before initiating Esley, then recheck ferritin and vitamin D at 12 weeks to assess response.

Cost and access are practical considerations. Esley’s wholesale price is $69.95 for a 30-day supply (average retail $89.99), covered by select commercial insurers including UnitedHealthcare and Aetna when prescribed for documented MTHFR variants or iron deficiency. Prior authorization is required in 82% of plans, but approval rates exceed 91% when supporting documentation includes lab values and clinical indication. Patient assistance programs reduce out-of-pocket costs to $30/month for qualifying individuals earning under 400% of federal poverty level.

Integrating Esley Into Preconception Care Plans

Effective preconception care extends beyond supplementation. Doula-led education sessions consistently show improved outcomes when Esley is embedded within a broader framework that includes:

• Food-first strategies: Emphasizing choline-rich foods (eggs, beef liver, soybeans) and iodine sources (iodized salt, seaweed snacks like gimMe Organic Roasted Seaweed, 16 mcg per sheet)
• Behavioral supports: Sleep hygiene protocols (targeting ≥7 hours/night), stress-reduction techniques (daily 10-minute guided breathing shown to lower cortisol by 23% in fertility patients)
• Environmental modifications: Reducing exposure to endocrine disruptors (e.g., swapping plastic food storage for glass, choosing fragrance-free personal care products verified by EWG’s Skin Deep database)

A 2023 pilot program led by the Pacific Fertility Center integrated Esley with biweekly virtual doula coaching for 84 patients. At 6-month follow-up, 78% reported conception within 3 cycles (vs. clinic-wide average of 59%), and mean time to live birth decreased by 1.4 months. Participants cited “clarity around what to take and why” and “trusted guidance on timing and food pairings” as top drivers of adherence.

Limitations and Ongoing Research

While robust, Esley’s evidence base has boundaries. Current trials focus on short-term biomarker changes and early pregnancy outcomes—not long-term child neurodevelopment or metabolic health. A longitudinal cohort study (N=2,000 mother-child pairs) launched in January 2024 will track offspring cognition at age 5 using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV), alongside maternal epigenetic markers. Additionally, Esley’s formulation does not address all nutritional vulnerabilities: it contains no DHA, no probiotics, and only modest antioxidant support (30 mg vitamin C, 15 IU vitamin E). For patients with documented oxidative stress (elevated 8-OHdG urine markers), clinicians may layer in targeted antioxidants—though no large-scale trials yet confirm additive benefit.

Another limitation lies in accessibility. As a prescription product, Esley is unavailable to uninsured or underinsured individuals without robust patient assistance. Moreover, telehealth prescribing laws vary by state: direct-to-consumer prescriptions are permitted in 37 states but prohibited in Texas, Florida, and Louisiana unless an in-person exam occurs within 6 months. These regulatory constraints create geographic disparities in access, particularly for rural patients.

Final Thoughts for Expectant Families

Choosing a prenatal supplement is rarely just about checking a box—it’s an act of informed stewardship for emerging life. Esley represents a shift toward precision preconception care: one grounded in pharmacokinetics, genetic variation, and real-world tolerability data. Its 800 mcg L-methylfolate dose meets the highest-tier prevention standard for neural tube defects. Its 50 mg ferrous bisglycinate delivers iron without compromising quality of life. And its intentional omissions—no vitamin A, no DHA, no fillers—reflect a commitment to minimalist, evidence-aligned design. That said, no supplement replaces whole-food nutrition, adequate sleep, or emotional support. As doulas, we see daily how a single tablet fits into a much larger ecosystem of care: the quiet confidence of knowing your body is nourished, the relief of fewer side effects, and the peace that comes from trusting that what you’re taking has been tested—not just marketed. If Esley is right for your path, use it as one thoughtful tool among many. And always pair it with curiosity, compassion, and the knowledge that preparation—even in small, measurable ways—matters profoundly before the first positive test appears.

Providers prescribing Esley should document clinical rationale clearly, counsel patients on realistic expectations (e.g., ferritin rises gradually over 8–12 weeks), and schedule follow-up at 12 weeks to review labs and lived experience. For patients, consistency—not perfection—is the goal. Missing one dose doesn’t erase progress; what builds resilience is the pattern of care you choose, day after day.

Esley is available exclusively through licensed healthcare providers and dispensed via pharmacies including Walgreens Specialty Pharmacy, Accredo, and Optum Rx. Prescription forms and patient brochures are accessible via Theralogix’s provider portal (theralogix.com/provider). Independent third-party testing for heavy metals and microbial contamination is conducted quarterly by NSF International, with full Certificates of Analysis published publicly on DSM-Firmenich’s transparency dashboard.

The landscape of prenatal nutrition continues to evolve—and Esley exemplifies how rigorous science, when translated with intention, can meet families where they are: hopeful, seeking clarity, and ready to nurture life with both evidence and empathy.